Thalassaemia alpha – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:56 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Thalassaemia alpha – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of SP-420 for Patients with Transfusion-Dependent Alpha or Beta Thalassemia https://clinicaltrials.eu/trial/study-of-sp-420-for-patients-with-transfusion-dependent-alpha-or-beta-thalassemia/ Wed, 29 Apr 2026 14:28:26 +0000 https://clinicaltrials.eu/trial/study-of-sp-420-for-patients-with-transfusion-dependent-alpha-or-beta-thalassemia/ This clinical trial is focused on studying a condition known as transfusion-dependent thalassemia, which includes both α-thalassemia and β-thalassemia. These are blood disorders that require regular blood transfusions. The trial will test a new treatment called SP-420, which is taken as a capsule. The purpose of the study is to find the right dose of SP-420 and to see how well it works in removing excess iron from the body over a period of 24 weeks.

Participants in the study will take SP-420 orally, which means they will swallow the capsules. The study will last for up to 48 weeks, during which the amount of iron in the body will be measured at different times. This will help researchers understand how much iron is removed by SP-420. The study will also monitor changes in the amount of iron in the liver using a method called magnetic resonance imaging (MRI), which is a type of scan that provides detailed images of the inside of the body.

Throughout the study, researchers will keep track of any side effects that participants might experience. The main goal is to determine how effective SP-420 is at reducing iron levels in people with transfusion-dependent thalassemia, while also ensuring the treatment is safe. Participants will be closely monitored by healthcare professionals to ensure their well-being during the trial.

]]> Study on Luspatercept for Treating Anemia in Adults and Adolescents with Alpha-Thalassemia https://clinicaltrials.eu/trial/study-on-luspatercept-for-treating-anemia-in-adults-and-adolescents-with-alpha-thalassemia/ Wed, 29 Apr 2026 14:23:59 +0000 https://clinicaltrials.eu/trial/study-on-luspatercept-for-treating-anemia-in-adults-and-adolescents-with-alpha-thalassemia/ This clinical trial is focused on studying the treatment of alpha-thalassemia, a blood disorder that affects the production of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. The study will use a medication called luspatercept, also known by its code name BMS-986346/ACE-536. Luspatercept is a type of protein designed to help improve the production of red blood cells in people with this condition. The trial will also involve a comparison with a placebo to evaluate the effectiveness of the treatment.

The purpose of the study is to determine how well luspatercept works in treating anemia, a condition characterized by a lack of healthy red blood cells, in adults with alpha-thalassemia. Additionally, the study aims to assess the safety and appropriate dosage of luspatercept in adolescents with the same condition. Participants in the study will receive either luspatercept or a placebo, and their response to the treatment will be monitored over a period of time. The study will look at how the treatment affects the need for blood transfusions and the levels of hemoglobin in the blood.

Throughout the study, participants will receive regular injections of the medication or placebo and will be closely monitored by healthcare professionals. The study will last for several months, during which time the safety and effectiveness of luspatercept will be evaluated. The goal is to find a safe and effective treatment option for people with alpha-thalassemia, potentially reducing their need for blood transfusions and improving their overall quality of life.

]]>